A Phase 4 interventional study of rosuvastatin in Hypertriglyceridemia, Hyperlipoproteinemia Type IV and Hyperlipoproteinemia Type V, sponsored by AstraZeneca. Completed at 3 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-16.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hypertriglyceridemia by AstraZeneca — none open to participants now, none under way, none of them phase 3. Hypertriglyceridemia · AstraZeneca.
Among the 12 studies in Hypertriglyceridemia by AstraZeneca, this one is the 6th largest by enrollment, is the only one that started in 2007, is the only one in phase 4, and was the 1st registered.
324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.
Browse Hypertriglyceridemia studies →None of the 12 studies in Hypertriglyceridemia by AstraZeneca is open now. The open studies under Hypertriglyceridemia, anywhere →
Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 5 · Phase 4 1
First in 2007; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 334 is above the median of 66 across 288 interventional studies indexed under Hypertriglyceridemia.
Median enrollment 224 across the 12 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Hypertriglyceridemia by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this trial is to determine if the treatment with rosuvastatin 10 and 20mg/day during 8 weeks in hypertriglyceridemic patients will reduce their triglyceride levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
10mg or 20mg
Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8)
Reduction from baseline to end of study
Time frame: 8 weeks
Non-HDL-C Reduction
Reduction from baseline to end of study
Time frame: 8 weeks
LDL-C Reduction
Reduction from baseline to end of study
Time frame: 8 weeks
Total Cholesterol Reduction
Reduction from baseline to end of study
Time frame: 8 weeks
HDL-C Increase
Increase from baseline to end of study
Time frame: 8 weeks
ApoA1 Levels
Change in the levels from baseline to end of study
Time frame: 8 weeks
hsCRP Reduction
Reduction from baseline to end of study
Time frame: 8 weeks
Adverse Events Reported
Number of participants with AEs and SAEs reported
Time frame: 8 weeks
ApoB Levels
Change in the levels from baseline to end of study
Time frame: 8 weeks
All participants where outpatients recruited from clinical centers. Recruitment began on August 2007 and ends on October 2008
| Milestone | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo |
|---|---|---|---|
| Started | 111 | 112 | 111 |
| Completed | 102 | 107 | 103 |
| Not completed | 9 | 5 | 8 |
| Withdrew: Lost to follow-up | 9 | 5 | 8 |
Reduction from baseline to end of study
| mg/dL | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo |
|---|---|---|---|
| Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8) | 67.95 ± 128.46 | 78.61 ± 121.51 | 22.31 ± 120.54 |
Reduction from baseline to end of study
| mg/dL | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo |
|---|---|---|---|
| Non-HDL-C Reduction | 52.76 ± 48.08 | 61.31 ± 46.63 | 1.06 ± 37.41 |
Reduction from baseline to end of study
| mg/dL | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo |
|---|---|---|---|
| LDL-C Reduction | 42.23 ± 28.58 | 53.22 ± 32.80 | -2.66 ± 28.78 |
Reduction from baseline to end of study
| mg/dL | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo |
|---|---|---|---|
| Total Cholesterol Reduction | 49.73 ± 41.13 | 63.32 ± 42.97 | -1.44 ± 34.98 |
Increase from baseline to end of study
| mg/dL | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo |
|---|---|---|---|
| HDL-C Increase | 3.49 ± 7.16 | 2.49 ± 5.78 | 1.95 ± 7.42 |
Change in the levels from baseline to end of study
| mg/dl | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo |
|---|---|---|---|
| ApoA1 Levels | 4.66 ± 23.38 | 6.79 ± 18.60 | 2.65 ± 19.40 |
Reduction from baseline to end of study
| mg/L | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo |
|---|---|---|---|
| hsCRP Reduction | 0.19 ± 1.16 | 0.11 ± 0.35 | -0.01 ± 1.00 |
Number of participants with AEs and SAEs reported
| Participants | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo |
|---|---|---|---|
| Adverse Events Reported | 27 | 29 | 20 |
Change in the levels from baseline to end of study
| mg/dl | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo |
|---|---|---|---|
| ApoB Levels | -27.05 ± 26.92 | -36.81 ± 23.51 | 1.43 ± 26.03 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin 10 mg | — | 1/111 (0.9%) | 9/111 (8.1%) |
| Rosuvastatin 20 mg | — | 0/112 (0%) | 12/112 (10.7%) |
| Placebo | — | 0/111 (0%) | 12/111 (10.8%) |
| Event | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo |
|---|---|---|---|
| Femur And Rotula Right Fracture That Required HospitalizationMusculoskeletal and connective tissue disorders | 1/111 | 0/112 | 0/111 |
| Event | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo |
|---|---|---|---|
| Upper respiratory infectionRespiratory, thoracic and mediastinal disorders | 3/111 | 5/112 | 5/111 |
| Urinary tract infectionRenal and urinary disorders | 1/111 | 1/112 | 3/111 |
| CephaleaNervous system disorders | 1/111 | 3/112 | 1/111 |
| PharyngotonsillitisRespiratory, thoracic and mediastinal disorders | 2/111 | 1/112 | 0/111 |
| Leg EdemaRenal and urinary disorders | 0/111 | 0/112 | 2/111 |
| DizzinessNervous system disorders | 1/111 | 2/112 | 1/111 |
| Back painMusculoskeletal and connective tissue disorders | 1/111 | 2/112 | 0/111 |
| Age Continuous(Years) | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo | Total |
|---|---|---|---|---|
| Age | 52.57 ± 12.77 | 53.14 ± 12 | 51.48 ± 13.47 | 52.4 ± 12.74 |
| Sex: Female, Male(Participants) | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 52 | 67 | 54 | 173 |
| Male | 59 | 45 | 57 | 161 |
| Arterial Hypertension(Participants) | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo | Total |
|---|---|---|---|---|
| Arterial Hypertension | 36 | 35 | 34 | 105 |
| Diabetes mellitus(Participants) | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo | Total |
|---|---|---|---|---|
| Diabetes mellitus | 12 | 16 | 13 | 41 |
| Body mass index continuous(Kg/m2) | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo | Total |
|---|---|---|---|---|
| Body mass index | 30.72 ± 5.11 | 29.77 ± 4.04 | 30.36 ± 4.90 | 30.28 ± 4.71 |
| HDL-C levels, continuous(mg/dL) | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo | Total |
|---|---|---|---|---|
| HDL-C | 33.50 ± 7.52 | 34.05 ± 6.88 | 32.30 ± 6.49 | 33.28 ± 6.99 |
| LDL-C, continuous(mg/dL) | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo | Total |
|---|---|---|---|---|
| LDL-C | 129.24 ± 28.23 | 130.51 ± 29.19 | 129.77 ± 31.10 | 129.84 ± 29.45 |
| TG levels, continuous(mg/dL) | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Placebo | Total |
|---|---|---|---|---|
| Tg levels | 319.51 ± 131.95 | 296.78 ± 95.19 | 309.46 ± 99.55 | 308.25 ± 110.22 |
The record gives a start of Jan 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin